top of page
  • Writer's pictureFutureMeds

FutureMeds Appoints John Allen as Managing Director of FutureMeds UK

Updated: Jan 24, 2023

Clinical trials not finishing on time is the #1 issue for bringing new drugs to market. FutureMeds presence in the U.K. and our network of medical research clinics will unlock an accelerated, 4 times more efficient trial process.

John Allen, with over 13 years of clinical trials management experience, will be responsible for leading FutureMeds’ UK operations and extending FutureMeds' network of medical research clinics into the United Kingdom. He assumed Managing Director responsibilities on 1 June 2021.

John, a Chartered Management Accountant with wide-ranging experience across a number of industries, has been in the clinical trials industry since 2008 and has held a number of senior financial and operational roles. Prior to joining FutureMeds John spent five years as Finance Director, EMEA for Accelerated Enrolment Solutions.

"The United Kingdom is a pivotal market for our clients and we are determined to support new drug development by enabling them to access our network of medical research clinics and transform trials with technology."

- Dr Radoslaw Janiak, CEO of FutureMeds.

FutureMeds is solely focused on clinical trials resulting in a higher number of patients with enhanced data quality which enables trials to be concluded faster. Opening the first FutureMeds site in the United Kingdom will be a significant step towards realising our goals and helping our clients to progress their clinical trials in a more professional and efficient manner.

"Joining FutureMeds is a great opportunity to contribute to and progress new drug development. I share the same passion for putting patients first as the FutureMeds' team and I am happy to use my expertise in helping FutureMeds in their mission of helping pharmaceutical companies provide Tomorrow’s Medicines Today" said John Allen.

About FutureMeds

FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.

FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.

Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.

Follow us on LinkedIn

Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.

bottom of page